Abstracts Archive - Page 390 of 2607 - ACR Meeting Abstracts

Abstract Number: 1407 • ACR Convergence 2023
Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA
Dafne Capelusnik¹, Sofia Ramiro², Elena Nikiphorou³, Walter P. Maksymowych⁴, Marina Nighat Magrey⁵, Helena Marzo-Ortega⁶ and Annelies Boonen⁷, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³King's College London, London, United Kingdom, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Case Western Reserve University, University Hospitals, Cleveland, OH, ⁶NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Presenteeism is associated with lower work satisfaction and future sick leave in axial spondyloarthritis (axSpA). It is generally assessed as a continuous variable; however,…
Abstract Number: 1373 • ACR Convergence 2023
Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome
Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Deltex1 is a transcription target of nuclear factor of activated T cells in mice and promotes T cell anergy. We have previously reported that…
Abstract Number: 1400 • ACR Convergence 2023
Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis
Sarah Abi Doumeth¹, Omer Pamuk² and Marina Nighat Magrey³, ¹Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ²Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH
Background/Purpose: ASDAS-CRP is a composite score that measures disease activity in axial spondyloarthritis (axSpA) and is based on patient-reported outcomes and objective measures of inflammation.…
Abstract Number: 1278 • ACR Convergence 2023
Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability
Manja van Wissen¹, Maaike gademan¹, Cornelia van den Ende², Max Teuwen¹, Wilfred Peter¹, Dirkjan van Schaardenburg³, Alfons den Broeder², Thea Vliet Vlieland⁴ and Salima van Weely¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Reade, Amsterdam, Netherlands, ⁴Leids University Medical Center, Leiden, Netherlands
Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
Abstract Number: 1404 • ACR Convergence 2023
Factor H-related protein-5 Exacerbates Pathological Bone Formation of Ankylosing Spondylitis
Chang-Nam Son¹, Ji-Hyun Lee¹, Sungsin Jo² and Tae-Hwan Kim³, ¹Uijeongbu Eulji Medical Center, Eulji University School of Medicine, UIJEONGBU, South Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: The complement factor H-related protein-5 (FHR-5), a member of the human factor H protein family, enhances complement activation. The influence of complement activation on…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 1417 • ACR Convergence 2023
Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration
Marion Pons¹, Simon Horskjær Rasmussen¹, Sara Nysom Christiansen¹, Brigitte Michelsen², Bente Glintborg¹, Bjorn Gudbjornsson³, Gerdur Maria Grondal⁴, Jiri Vencovsky⁵, Anne Gitte Loft⁶, Ziga Rotar⁷, Katja Perdan Pirkmajer⁸, Michael Nissen⁹, Burkhard Moeller¹⁰, Gary Macfarlane¹¹, Gareth T. Jones¹¹, Florenzo Iannone¹², Roberto F. Caporali¹³, Karin Laas¹⁴, Sigrid Vorobjov¹⁵, Daniela Di Giuseppe¹⁶, Belkis Nihan Coskun¹⁷, Burcu Yagız¹⁷, Sella Provan¹⁸, Karen Fagerli¹⁸, Isabel Castrejon¹⁹, Lucia Otero-Valera²⁰, Marleen van de Sande²¹, Irene van der Horst-Bruinsma²², Dan Nordstrom²³, Laura Kuusalo²⁴, Elsa Vieira-Sousa²⁵, Miguel Bernardes²⁶, Tor Olofsson²⁷, Jana Baranová²⁸, Merete Hetland¹, Mikkel Østergaard²⁹ and Lykke Ørnbjerg¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁵Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Aarhus University, Horsens, Denmark, ⁷University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ⁹Geneva University Hospitals, Geneva, Switzerland, ¹⁰Inselspital - University Hospital Bern, Bern, Switzerland, ¹¹Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ¹⁴Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹⁵National Institute for Health Development, Tallinn, Estonia, ¹⁶Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Rheumatology, Bursa Uludag University, Bursa, Turkey, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁰Spanish Society of Rheumatology, Madrid, Spain, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²³Helsinki University Hospital, Helsinki, Finland, ²⁴Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ²⁵Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ²⁶Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ²⁷Lund University and Skåne University Hospital, Lund, Sweden, ²⁸Institute of Biostatistics and Analyses, Brno, Czech Republic, ²⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Patient reported outcomes (PROs) are important in the treatment evaluation of patients with spondyloarthritis, including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). For secukinumab,…
Abstract Number: 1409 • ACR Convergence 2023
Analysis of Soluble Biomarkers in Axial Spondyloarthritis
Caroline Bauchiero¹, Stephanie Sinnappan² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Distinguishing patients with axial spondyloarthritis (axSpA) from patients with other causes of chronic back pain remains a challenge. The lack of reliable biomarkers contributes…
Abstract Number: 1420 • ACR Convergence 2023
Changes in Serum Cytokines and Collagen Proteins Correlate with Durability of Guselkumab Efficacy and Continued Disease Improvement Through 2 Years in Patients with Active Psoriatic Arthritis
Stefan Siebert¹, Georg Schett², Siba Raychaudhuri³, Monica Guma⁴, Warner Chen⁵, Sheng Gao⁶, Soumya Chakravarty⁷, May Shawi⁸ and Proton Rahman⁹, ¹School of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom, ²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ³UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ⁴San Diego VA Healthcare Service, La Jolla, CA, ⁵Translational Sciences, Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁸Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁹Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada
Background/Purpose: In the phase 3 DISCOVER-2 study of biologic-naïve patients (pts) with active psoriatic arthritis (PsA), guselkumab (GUS), a fully human, selective interleukin (IL)-23p19 subunit…
Abstract Number: 1416 • ACR Convergence 2023
Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis
Ulf Lindström¹, Daniela Di Giuseppe², Sofia Exarchou³, Gerd-Marie Alenius⁴, Tor Olofsson⁵, Eva Klingberg¹, Lennart Jacobsson⁶, Johan Askling² and Johan Karlsson Wallman⁵, ¹University of Gothenburg, Gothenburg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Lund University, Åkarp, Sweden, ⁴Umeå University, Umeå, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶University of Gothenburg, Malmö, Sweden
Background/Purpose: In many countries, methotrexate (MTX) monotherapy is the first-line disease-modifying anti-rheumatic drug (DMARD) therapy for psoriatic arthritis (PsA), despite that its efficacy in PsA…
Abstract Number: 1399 • ACR Convergence 2023
Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data
Ansaam Daoud¹, Sadeer Al-Kindi² and Marina Nighat Magrey³, ¹University Hospitals, Case Western Reserve University, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH
Background/Purpose: Ankylosing Spondylitis (AS) is associated with an increased risk of cardiovascular disease, partly due to systemic inflammation, and an increased risk of vascular mortality.…
Abstract Number: 1408 • ACR Convergence 2023
Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort
Ji In Jung¹, Ju Yeon Kim², Jin Kyun Park³, Eun Young Lee³, Eun Bong Lee² and Jun Won Park², ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Although previous studies suggested that physical functioning is largely driven by disease activity in patients with spondyloarthritis (SpA), its relationship to radiographic progression has…
Abstract Number: 1398 • ACR Convergence 2023
A Deep Learning Algorithm for MRI Spinal Inflammation in Axial Spondyloarthritis
Shirley Chiu Wai Chan¹, Ying Ying Lin², Ho Yin Chung¹, Kam Ho Lee³ and Peng Cao², ¹Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong, ²Department of Diagnostic Radiology, the University of Hong Kong, Hong Kong, Hong Kong, ³Department of Radiology, Queen Mary Hospital, Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Deep learning has achieved wide applications in different areas of medical imaging analysis. Limited studies have explored the use of deep learning for imaging…
Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Bon San Koo¹, Subin Hwang¹, Ye-Jee Kim², Soo Min Ahn² and Wook Jang Seo³, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
Abstract Number: 1410 • ACR Convergence 2023
The Use of the ASAS Referral Criteria Together with Increased Education and Training of Its Use Improves Delay to Diagnosis of Axial Spondyloarthritis
Antoni Chan, Kathryn Rigler and Arran McDougall, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Early diagnosis of axial spondyloarthritis (AxSpA) remains a challenge in the management of this condition worldwide. Over the last decade, there remains a significant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].